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1. Introduction 
All anurans produce venomous skin secretions composed by a complex mixture of bioactive 
peptides used against potential predators and pathogens that have evolved in a predator-
prey interaction and defence against a microbial invasion scenario. Each new species 
studied reveal new molecules, homologous to hormones, neurotransmitters, antimicrobials, 
as well as several others with unknown biological activity. The vast majority of species have 
yet to be studied. Recently, these secretions have also been reported as a rich source of 
multiple antimicrobial peptides against multidrug-resistant strains of bacteria, fungi, 
protozoa, and virus, including cancer, providing several instructive lessons for the 
development of new and more efficient nanotechnology based therapies for infectious 
disease treatment. However, new drugs arising from the identification and analysis of 
bioactive peptides from anuran biodiversity are threatened by amphibian decline. Nearly 
one-third of amphibian species are globally threatened with extinction or extinct due the 
effects of climate change, reduction and modification of natural habitats, pollution, as well 
as emerging diseases. Unfortunately, conservation efforts have not been sufficient enough to 
counter balance the decline in amphibian species. As a result, several species have already 
become extinct before their peptidome can be evaluated, and others could disappear, which 
would seriously inhibit understanding required for the development of important new 
therapies against the superbugs and degenerative diseases. This situation requires drastic 
strategies in order to build robust anuran peptide libraries and biological anuran tissue 
banks in order to conserve part of this biological richness. In this chapter, the knowledge of 
anuran peptide and its potential for the development of new and more effective therapies 
based on a nanotechnological approach against superbugs that is threatened by amphibian 
decline are presented.  
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2. Anuran amphibians: Origen, evolution and distribution 
Modern amphibians belong to the subclass Lissamphibia, super order Salientia, and can be 
scientifically subdivided into three orders: Anura, which includes frogs and toads, is the 
largest group with more than 6,000 species; Caudata, which includes salamanders and newts, 
with 608 species; and Gymnophiona, the least-known group, which are commonly referred to 
as caecilians, with 189 species. According to the AmphibiaWeb database, numbers of new 
species have grown rapidly over the last 20 years or so. Since 1985 the total number of 
recognized species has increased by over 60%, one reflex of the growing interest in 
biodiversity knowledge. Currently, each new area researched shows new species, one 
example is the Amazon Forest, where between 1999 to 2009, 216 new species were 
discovered (Thompson, 2010). 
The origin of amphibians can be traced back to the Devonian period (about 
416 to 359 million years ago). They were developed from a common ancestor similar to the 
modern day coelacanth, considered as the "missing link" between fish and tetrapods (Long 
& Gordon, 2004). When amphibians first appeared, Earth’s terrestrial area was essentially 
one giant landmass inhabited by plants and insects. Amphibians were the first vertebrates to 
make the transition from water to land (Mattoon, 2001). Somehow, a type of bony fish 
evolved into a creature that had four legs, could breathe atmospheric oxygen instead of 
dissolved oxygen, and had a body structure that allowed it to manoeuvre without the 
support of water (Mattoon, 2001). During the Carboniferous Period (around 359 to 299 
million years ago) amphibians moved up in the food chain and occupied the ecological 
position that presently belongs to crocodiles. These amphibians were notable for their ability 
to use the mega insects on land and many types of fish as an energy source. However, 
during the Triassic Period (250 to 200 million years ago), the better land-adapted proto-
crocodiles began to compete with amphibians for food and space (Mattoon, 2001), which, in 
turn, reduced their energy sources significantly, leading the amphibians to a dramatic 
reduction in their average size, and consequently a dropping position in the food chain. 
Modern anurans originated from these amphibians that had to adapt to new environment 
challenges in order to survive extinction. 
The anuran order is the most diverse group of vertebrates, with more than 6,000 known 
species, a total, which is being added to annually by the discovery of new species. This order 
is subdivided into three suborders: Archaeobatrachia, which includes four families of 
primitive frogs; Mesobatrachia, which includes five families of more evolutionary 
intermediate frogs; and Neobatrachia, so far the largest group, which contains the remaining 
families of modern frogs, including most common species throughout the world (Table 1). 
The families Leptodactylidae, Hylidae and Ranidae belonging the Neobatrachia suborder 
are the richest in number of species.  
Anurans are to be found in both tropical and subarctic regions with the exception of some 
ocean islands, a few deserts and Arctic and Antarctic regions (Figure 1) (Frost et al., 2008). 
The majority of anuran species are found in the tropical rainforests. According to the 
Brazilian Herpetological Society, Brazil has at least 847 anuran species (Brazilian 
Herpetological Society [SBH], 2011), approximately 15% of the world anuran fauna, this 
represents the greatest number of amphibians for any country on Earth, and is closely 
followed by Colombia. Both South American countries have received extensive survey 
efforts in recent decades, and although both countries can be expected to add significantly to 
their totals, the level of increase is likely to be less than in some of the other highly diverse 
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countries (International Union for Conservation of Nature and Natural Resources [IUCN], 
2011). Within South America, Peru in particular is relatively poorly researched and is almost 
certain to rise very substantially in its species total (IUCN, 2011). 
 
 
Fig. 1. Global patterns of amphibian diversity are shown. This diversity map clearly shows 
certain areas of high global diversity, including tropical South America and tropical West 
Africa. However, the problem of uneven survey efforts around the world complicates 
interpretation of this map. Regions such as Indonesia, New Guinea and the Congo Basin are 
especially likely to be under represented on this map due to lack of adequate surveys 
(Extracted from IUCN, 2011; Copyright 2011 International Union for Conservation of Nature 
and Natural Resources - Red List Unit). 
3. Amphibian decline: The biodiversity crisis 
According to the International Union for the Conservation of Nature (IUCN), amphibians 
may be the only major group currently at risk globally. IUCN assesses the status of species 
on a global scale and maintains a database of species that face a high risk of global 
extinction: the IUCN Red List of Threatened Species. The IUCN Red List, recent detailed 
worldwide assessment and subsequent updates show that nearly one-third of species 
(32.4%) are either globally extinct or threatened with extinction (Critically Endangered, 
Endangered and Vulnerable), representing 2,030 species (IUCN, 2011). McCallum (2007) 
estimates that current rates of extinction are 211 times the background extinction rate for 
amphibians, and rates would be as high as 25,000–45,000 times greater if all of the currently 
threatened species become extinct. If this is allowed to continue, the projected losses would 
constitute the largest mass extinction since the disappearance of the dinosaurs, which many 
scientists argue would be the sixth great mass extinction (Wake & Vredenburg, 2008).  
Several long-term studies performed on intact natural ecosystems such as Yellowstone 
National Park and Sierra Nevada of California in United States (Noss et al., 2002; 
Vredenburg et al., 2007), Eungella National Park in Australia (McDonald, 1990), and  
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Monteverde Cloud Forest Preserve in Costa Rica (Pounds et al., 1997) show a worldwide 
decline in amphibian species in the last two decades. Populations of many species of frogs 
have declined dramatically in relatively undisturbed habitats at high altitudes and 
anthropized areas throughout the world (Blaustein & Wake, 1990, 1995; Blaustein et al., 
1994; Bradford, 1991; Campbell, 1999; Carey, 1993; Collins & Storfer 2003; Crump et al., 1992; 
Czechura & Ingram, 1990; Hero et al., 2005; Kiesecker et al., 2001; McDonald, 1990; 
McMenamin et al., 2008; Pounds et al., 2006; Pounds, 2001; Reading, 2007; Richards et al., 
1993; Skerratt et al., 2007; Stuart et al., 2004; Young et al., 2001). A map produced by IUCN 
shows the global distribution of threatened amphibians (Figure 2) revealing that the greatest 
concentration of threatened amphibian are in relatively limited areas dominated by species 
living within specific ranges, often living in mountainous areas. Many of these species have 
been subjected to severe habitat loss, and exposure to the fungal disease chytridiomycosis 
(Frost et al., 2008; IUCN, 2011).  
 
 
Fig. 2. Global distribution of threatened amphibians. Number of threatened species is show 
in red. Important concentrations of threatened species are to be found from Southern 
Mexico to Ecuador and Venezuela, as well as the Greater Antilles, Atlantic Forests of 
southern Brazil, upper Guinea forests of western Africa, forests of western Cameroon and 
eastern Nigeria, Albertine Rift of eastern central Africa, Eastern Arc Mountains of Tanzania, 
Madagascar, western Ghats of India and Sri Lanka, Borneo and Philippines, eastern 
Australia, central and southern China (Extracted from IUCN, 2011; Copyright 2011 
International Union for Conservation of Nature and Natural Resources Red List Unit). 
Atmospheric and water pollution, pathogens, exotic species, UV irradiation, and habitat 
destruction and/or modification have all contributed to the current amphibian decline 
(Alford & Richards, 1999; Blaustein et al., 2003; Collins & Storfer, 2003). Climatic change 
poses an additional serious threat to populations as is seen by precipitous decline of 
amphibian populations in remote and preserved areas. This data indicates that this 
phenomenon is linked to landscape and environmental changes brought about by global 
climatic change (Alford et al., 2007; Beebee, 1995; Carey & Alexander, 2003; McMenamin et 
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al., 2008; Pounds et al., 2006; Reading, 2007; Wake, 2007). According to McMenamin and co-
workers (2008), changes in climate can affect amphibian populations in many ways, three of 
which we detail here (Figure 3). 
 
 
Fig. 3. Flow chart of global climatic change impacts on amphibian populations. These 
mechanisms are affecting amphibian populations worldwide. Solid lines denote clearly 
established relationships. (Extracted from McMenamin et al., 2008, Copyright 2011 National 
Academy of Sciences, U.S.A.). 
Some examples of amphibian populations loss are catastrophic, as has been observed in 
Monteverde Cloud Forest Preserve in Costa Rica by Pounds and co-workers (1997) that 
performed a 5-year study involving daily monitoring of a large amphibian fauna 
demonstrating that 20 species of frogs, representing 40% of the total population, have been 
lost at the Preserve. What is especially notable about this case is that these observations 
discount the hypothesis of habitat destruction or modification, the most common reason for 
species disappearance, because the Preserve has a highly protected status. According to 
Wake & Vredenburg (2008), the start of this decline was observed in the late 1980s, where at 
the same time disappearances of species of the unique gastric brooding frogs from Australia 
(Rheobatrachus) occurred in protected areas in the Australian wet tropics (McDonald, 1990). 
According the same authors, at first all of these declines recorded were enigmatic, but 
eventually two primary causal factors emerged: the infectious disease chytridiomycosis and 
global warming (Lips et al., 2006; Pounds et al., 2006). 
The chytridiomycosis is an emerging panzootic fungal disease caused by the chytrid fungus 
Batrachochytrium dendrobatidis. This disease was first described in 1998 from moribund and 
dead adult amphibians collected at sites of mass deaths in Australia and Panama between 
1993 to 1998 (Berger et al., 1998). Symptoms of this amphibian lethal disease include 
abnormal posture, extension of hind limbs, convulsions, lethargy, and loss of attempt to 
escape danger; roughening of the skin; gross lesions consisting of abnormal epidermal 
shedding and ulceration; hemorrhages in the skin, muscle, or eye; hyperemia of digital and 
ventrum skin, and congestion of viscera (Berger et al., 1999; Daszak et al., 1999). According 
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to Berger and co-workers (1998), three mechanisms by which chytridiomycosis causes death 
have been proposed: epidermal hyperplasia impairs essential cutaneous respiration or 
osmoregulation; a fungal toxin is absorbed systemically; and a combination of both factors 
(Berger et al., 1998, Pessier et al., 1999).  
In 2006, Pounds and co-workers hypothesized that climate change, precipitation, and 
increased temperature have acted synergistically in favour of the growth of the infectious 
chytrid fungus. This hypothesis is based on a situation where global warming has shifted 
temperatures closer to the presumed optimal conditions for B. dendrobatidis. 
According the scientists of the Intergovernmental Panel on Climate Change (IPCC), human 
activities are the main cause of climate change, and will be responsible for the estimated 
temperature rise during the next century, that is projected to be between 2°C to 4°C, but 
rising as high to 7°C for much of the United States and Europe, with even higher 
temperatures expected in northern Eurasia, Canada, and Alaska (Parry et al., 2007). This 
change will produce a devastating effect on amphibian species. Impacts of the different 
warming scenarios are all dramatic and severe, where the first event predicted by the IPCC 
panel, ‘‘Amphibian Extinctions Increasing on Mountains’’, is now an empirical fact (see: 
http://www.ipcc.ch/graphics/ar4-wg2/jpg/ts6.jpg). 
Multiple factors acting synergistically are contributing to the loss of amphibians. The 
association of extrinsic forces, such as global warming and increased climatic variability that 
increases the susceptibility of high-risk species (those with small geographic ranges, low 
fecundity, and specialized habitats), with habitat modification and destruction, use of 
fertilizers and pesticides, introduction of pollutants and exotic organisms, have severely 
impacted upon amphibians (Hayes et al., 2002; Sodhi et al., 2008; Wake & Vredenburg, 
2008). According to Cunningham and co-workers (2006), the emergence of new infectious 
diseases produced by the expansion of human populations into new habitats have 
consequences for many other species, such as the case of chytridiomycosis in amphibians.  
The IUCN has been producing lists of threatened species since the 1960s (Burton, 2003; Scott et 
al., 1987) reporting the very serious situation facing amphibians globally, which may be 
indicative of the state of freshwater species as a whole. Amphibians are declining more quickly 
than either birds or mammals (Stuart et al., 2004). The IUCN Red List of Threatened Species 
shows that at least 1,622 of the known anuran species on Earth are known to be threatened 
with extinction (IUCN, 2011). In 2008, a total of 120 amphibian species are listed as Critically 
Endangered (Possibly Extinct), and the majority of these could have disappeared since 1980 
(Baillie et al., 2004; Vié et al., 2009). Because the amphibian extinctions are happening so fast 
and only a few areas on earth have been monitored by an insufficient number of scientists, it is 
difficult to obtain a complete current picture of the amphibian population status (Maas, 2011). 
The indications show that the extinction of amphibians is the most serious wave of all 
extinctions currently taking place, but the situation may be even graver than the numbers 
suggest (Baillie et al., 2004; Crawford et al., 2010; IUCN, 2011).  
Several families of amphibians appear to be disproportionately threatened, in particular the 
Hynobiidae (Asian salamanders), Plethodontidae (lungless salamanders), Astylosternidae 
(Cameroonian stream frogs), Bufonidae (true toads), Rhacophoridae (Asian tree frogs), 
Leptodactylidae (typical Neotropical frogs), Leiopelmatidae (New Zealand frogs), 
Nasikabatrachidae (Indian burrowing frog), Rhinodermatidae (Darwin’s frogs), and 
Sooglossidae (Seychelles frogs). Both members of the Rheobatrachidae (gastric-brooding 
frogs) are now Extinct, representing the loss of an entire vertebrate family (Baillie et al., 
2004). It is important to note that some biologists class them within Myobatrachidae under 
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the subfamily Rheobatrachinae, but others place them within their own family, 
Rheobatrachidae (Heyer & Liem, 1976).  
In spite of the massive deaths, some amphibian species appear to have an innate capacity to 
withstand chytridiomycosis infection. Even within species that generally succumb, some 
populations survive, possibly demonstrating that these anuran populations are being 
subjected to a selection process. According to Wake & Vredenburg (2008), despite these 
alarming estimates, some anuran species, particularly these that are invasive, are apparently 
doing very well in many parts of the world, and many thrive in landscapes heavily modified 
by human activities, such as the Cane Toad (Rhinella marina), the American Bullfrog (Rana 
catesbeiana), and the Clawed Frog (Xenopus laevis). They have shown they are not afflicted by 
chytridiomycosis. 
This massive loss of anuran species diversity will produce a severe impact upon the 
ecosystem and human life brought about because amphibians consume huge quantities of 
invertebrates, including humanity's most vilified pests; play a crucial role in global 
ecosystems, both as predator and prey, help maintain healthy functioning environments; 
some species are an important protein source in many subsistence cultures and are traded in 
their millions as food and pets; the skin secretions that protect amphibians against predators 
and infection have been found to contain important pharmaceutical compounds that show 
potential in treating a variety of illnesses from HIV to cancer. One of these dramatic 
examples is the Golden Toad Bufo periglenes from Costa Rica, extinct since 1989 (Baillie et al., 
2004), before its interesting chemical composition and potential applications could be 
evaluated by researches from different scientific areas.  
4. Anuran skin protective adaptations 
The anuran skin presents morphofunctional and behavioral protective adaptations against a 
number of adverse factors in the terrestrial environment (Barra & Simmaco, 2005). The 
cutaneous glands present in the skin play an essential role in respiration, reproduction, 
protection against desiccation and defence against predators and infection by 
microorganisms on the body surface (Toledo & Jared, 1995). Secretions produced by these 
glands have a key role in the protection by the presence of complex chemical composition 
with noxious or toxic substances with diverse pharmacological effects, which constitute an 
important source of biologic active compounds against bacteria, fungi, protozoa, virus and 
cancer (Calderon et al., 2009, 2010, 2011). However, the majority of the anuran species have 
not had their gland content examined by science and so remain unknown. 
The cutaneous gland ultrastructural characterization of all living amphibians demonstrates 
that they usually belong to four main types located in the spongious dermis differing from 
others in size and secretory activity, and can be classified as: mucous, serous (granular or 
poison), lipid (or wax), and mixed (seromucous) glands (Almeida et al., 2007; Brizzi et al., 
2002; Duellmann & Trueb, 1994; Lacombe et al., 2000). 
Each gland presents specific action in homeostasis behavior: lipid glands promote the 
impermeabilization of the skin in order to decrease water loss (Castanho & De Luca, 2001); 
mucous glands produce mucus to support cutaneous functions, such as respiration, 
reproduction, thermoregulation, and defence (Toledo & Jared, 1995); serous glands, that are 
the largest and most widely distributed over the animal’s body surface, act as a main 
element in amphibian passive chemical defence (Lacombe et al., 2000; Toledo & Jared, 1995). 
Thus, the mixed gland contains both mucous and serous cells (de Brito-Gitirana, 2004). 
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The serous glands produce a wide variety of noxious or toxic substances with diverse 
pharmacological effects on microorganisms, vertebrate, and invertebrate species (Toledo & 
Jared 1995; Lacombe et al., 2000). The serous glands exhibit remarkable polymorphism, 
having been classified into two classes, type I and II (Delfino et al., 1998; Lacombe et al., 
2000). Type I glands exhibit a poorly developed smooth endoplasmic reticulum (Lacombe et 
al., 2000) and present two subtypes, Ia and Ib. Type Ia has dense granules that characterize 
the biosynthesis of proteinaceous products for exocytosis, which engage both rough 
endoplasmic reticulum and Golgi apparatus (Delfino, 1991). Type Ib has vesicles holding a 
lucent material in the fluid serous secretion on the anuran skin (Toledo & Jared, 1995). Type 
II glands present a well-developed smooth endoplasmic reticulum that is potentially 
engaged in the biosynthesis of peptides (Blaylock et al., 1976; Lacombe et al., 2000). These 
peptides are produced as prepropeptides, which have to be processed into mature peptides 
by the removal of the signal and acidic components, and then stored in the granules (Nicolas 
& El Amri, 2009).  
Some anurans, such as the bufonidaes (toads) have a pair of peculiar glandular structures 
symmetrically disposed in a post-orbital position named as parotoid glands (Young, 1985). 
These glands are composed of large aggregations of granular glands responsible for the 
production and storage of a thick and creamy secretion, which contribute to protection 
against predators and parasites (Clarke, 1997; Croce et al., 1973; Duellman & Trueb, 1994; 
Sakate et al., 2000). The parotoid gland is an integument region, in which three exocrine 
glandular types occur: mixed glands, smaller granular glands and larger granular glands. 
The mixed gland is formed by mucous and serous cells while the small granular glands 
contain a homogene acidophilic intake. The larger granular glands produce a basophilic and 
alcianophilic material, and are responsible for the macroscopic protuberances designed as 
parotoid glands. Thus, the end product released by the parotoid glands is a mix of secretions 
produced by the three glands (Almeida et al., 2007). 
It is accepted that the release of the gland content onto the skin surface is mediated by a 
holocrine mechanism that involves rupture of the plasmatic membrane and extrusion of the 
granules through a duct opening onto the surface (Nicolas & El Amri, 2009). 
Immunofluorescence analysis of Phyllomedusa bicolor (Hylideae) dermal glands using an 
antibody to the acidic propiece region of the preprodermaseptin/preprodeltorphins-derived 
peptide family [ENENEENHEEGSE] demonstrated that the fluorescence-positive reaction is 
restricted to the serous glandular content, indicating their specific role in the biosynthesis 
and secretion of dermaseptins and deltorphin peptides (Lacombe et al., 2000). Additionally, 
mass spectrometry image (MALDI-image) performed with the skin of P. hypochondrialis 
(Hylideae) indicated that the serous glands present specialization in the peptide production 
and storage (Brand et al., 2006b). 
In spite of the large number of anuran species from different genera, a great deal of attention 
is being paid to the study of neotropical hylid frogs that belong to the subfamily 
Phyllomedusinae, as an excellent source of peptides. In 1985, Vittorio Erspamer also stated 
that ‘‘No other amphibian skin can compete with that of the Phyllomedusae’’ (Erspamer et 
al., 1985). The initial efforts on Phyllomedusa skin secretions by V. Erspamer followed by 
other scientists around the world during the last four decades has revealed a complex 
profile of biologically active peptides with antimicrobial, hormonal, and neuro activities 
(Calderon et al., 2011). These peptides differ significantly among species within this genus 
leading to an interesting molecular diversity, possibly associated with specific differences 
presented in the specie niche, such as interactions with the environment, predators, and 
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pathogens that characterize hylid species evolution (Amiche et al., 1993; Bevins & Zasloff, 
1990). 
5. Frog skin active peptides family: Defence against pathogens and predators 
The complex chemical composition of anuran skin secretions constitutes a rich chemical 
warehouse of a wide number of natural biologically active compounds, such as amines, 
steroid derivatives, alkaloids and peptides. Peptides from anuran skin secretion are grouped 
into the Frog Skin Active Peptide (FSAP) family. The FSAP family can classify into three 
main groups according to their primary activity: antimicrobial peptides (AMPs); smooth 
muscle active peptides; and nervous system active peptides (Calderon et al., 2011; Erspamer 
et al., 1981). The secondary activities of FSAPs were not considered in this systematization. 
The first group acts as a skin anti-infective passive defence barrier, the second and the third 
groups cause the disruption of the predator homeostasis balance (Calderon et al., 2011). 
However, the biological activity of several peptides from anuran skin remains unknown. 
The antimicrobial peptides (AMPs) compose the innate immunity system of anurans against 
microbial invasion (Giuliani et al., 2008; Radek & Gallo, 2007; Zasloff, 2002) effective against 
multidrug resistant strains of bacteria, fungi, protozoa, and virus including cancer, and 
provide instructive lessons for the development of new and more efficient 
nanotechnological-based therapies for infectious and degenerative diseases treatment 
(Calderon et al., 2011; Rinaldi, 2002). Many AMPs possess a wide range of activity showing 
effectiveness against diverse microorganism strains. One example is the dermaseptin family 
of AMPs and their analogs from the skin of Phyllomedusinae species. Dermaseptins have in 
vitro lytic activity against a broad spectrum of free-living microorganism strains, including 
wall-less, Gram-negative and Gram-positive bacteria, fungi, protozoa, and virus, as shown 
above (Table 1). Despite the sequence similarities, the dermaseptins differ in their action 
efficiency (Nicolas & El Amri, 2009; Rivas et al., 2009). However they present rapid and 
irreversible antimicrobial effect and no toxic effects in mammalian cells in vitro 
(Kustanovich et al., 2002; Navon-Venezia et al., 2002).  
In additiony to antimicrobial activity, some dermaseptins present other additional biological 
functions that have unclear relations with pathogen clearance, e.g., dermaseptin B2 
(adenoregulin) stimulates the binding of agonists to A1 adenosine receptors and also 
enhances the binding of agonists to several G-protein coupled receptors in rat brain 
plasmatic membrane through a mechanism involving enhancement of guanyl nucleotide 
exchange at G-proteins (Shin et al., 1994); Dermaseptin-B4 stimulates insulin release by 
acute incubation with glucose-responsive cells (Marenah et al., 2004); Dermaseptin-S1 
stimulates the production of reactive oxygen species and release of myeloperoxidase by 
polymorphonuclear leukocytes (Ammar et al., 1998). 
Gram-negative Salmonella typhimurium, wall-less Mycoplasma gallisepticum and M. mycoides 
show resistance to dermaseptin B9 from P. bicolor (Fleury et al., 1998).  
Antimicrobial peptides are part of the innate immunity system of anurans against microbial 
invasion (Giuliani et al., 2008; Zasloff, 2002; Radek & Gallo, 2007). Crafted by evolution into 
an extremely diversified array of sequences and folds, AMPs share a common amphiphilic 
3-D arrangement (Giuliani et al., 2008). This feature is directly linked to a common 
mechanism of action that predominantly develops upon interaction of peptides with cell 
membranes of target cells (Giuliani et al., 2008). The mechanisms of action of AMPs in 
microbial membranes are complex and still relatively unknown, but they constitute a  
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Microorganisms 
susceptible to 
dermaseptins 
Dermaseptins 
active against 
microorganism 
Species where 
the dermaseptin 
was identified 
References 
Wall less bacteria    
Acholeplasma laidlawii B9 P. bicolor Fleury et al., 1998 
Spiroplasma apis B9 P. bicolor Fleury et al., 1998 
Spiroplasma citri B9 P. bicolor Fleury et al., 1998 
Spiroplasma floricola B9 P. bicolor Fleury et al., 1998 
Spiroplasma melliferum B9 P. bicolor Fleury et al., 1998 
Gram-negative bacteria    
Aerornonas caviae B1 P. bicolor Strahilevitz et al., 1994 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Acholeplasma laidlawii B9 P. bicolor Fleury et al., 1998 
Acetobacter calcoaceticus O1 P. oreades Brand et al., 2002 
Escherichia coli B1, B9 P. bicolor Fleury et al., 1998; Strahilevitz et al., 
1994 
 D1, D2, D3, D4, D5 P. distincta Batista et al., 1999 
 H1 P. hypochondrialis Brand et al., 2006b; Conceição et al., 
2006 
 O1 P. oreades Brand et al., 2002; Leite et al., 2008 
 T7 P. tarsius Silva et al., 2000 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Neisseria gonorrhoeae S4 P. sauvagii Rydlo et al., 2006; Zairi et al., 2009 
Pseudomonas aeruginosa B9 P. bicolor Fleury et al., 1998 
 D1, D2, D3, D4, D5 P. distincta Batista et al., 1999 
 H1 P. hypochondrialis Brand et al., 2006b; Conceição et al., 
2006 
 O1 P. oreades Brand et al., 2002; Leite et al., 2008 
 T7 P. tarsius Silva et al., 2000 
Gram-positive bacteria    
Corynebacterium 
glutamicum 
B9 P. bicolor Fleury et al., 1998 
Enterococcus faecalis D1, D2, D3, D4, D5 P. distincta Batista et al., 1999 
 T7 P. tarsius Silva et al., 2000 
Micrococcus luteus H1 P. hypochondrialis Conceição et al., 2006 
Nocardia spp O1 P. oreades Leite et al., 2008 
Nocardia brasiliensis B1 P. bicolor Strahilevitz et al., 1994 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Staphylococcus aureus B1, B9 P. bicolor Fleury et al., 1998; Strahilevitz et al., 
1994 
 D1, D2, D3, D4, D5 P. distincta Batista et al., 1999 
 H1 P. hypochondrialis Brand et al., 2006b; Conceição et al., 
2006 
 O1 P. oreades Brand et al., 2002; Leite et al., 2008 
 T7 P. tarsius Silva et al., 2000 
Streptococcus dysgalactiae  O1 P. oreades Leite et al., 2008 
Streptococcus uberis O1 P. oreades Leite et al., 2008 
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Microorganisms 
susceptible to 
dermaseptins 
Dermaseptins 
active against 
microorganism 
Species where 
the dermaseptin 
was identified 
References 
Fungi    
Aspergillus fumigatus S1, S2 P. sauvagii Mor & Nicolas, 1994 
Arthroderma simii B1 P. bicolor Strahilevitz et al., 1994 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Cryptococcus neofonnans B 1 P. bicolor Strahilevitz et al., 1994 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Candida albicans B 1 P. bicolor Strahilevitz et al., 1994 
 O1 P. oreades Leite et al., 2008 
 S1, S2, S4 P. sauvagii Mor & Nicolas 1994; Zairi et al., 2008 
Candida tropicalis D1, D2 P. distincta Leite et al., 2008 
 O1 P. oreades Leite et al., 2008 
Candida guilliermondii D1, D2 P. distincta Leite et al., 2008 
 O1 P. oreades Leite et al., 2008 
Microsporum canis B1 P. bicolor Strahilevitz et al., 1994 
 S1, S2 P. sauvagii Mor & Nicolas, 1994 
Tricophyton rubrum S1, S2 P. sauvagii Mor & Nicolas, 1994 
 B 1 P. bicolor Strahilevitz et al., 1994 
Protozoa    
Leishmania major (Pro) S1, S4 P. sauvagii Feder et al., 2000; Gaidukov et al., 
2003; Kustanovich et al., 2002 
Leishmania mexicana (Pro) S1 P. sauvagii Hernandez et al., 1992; Mor & 
Nicolas 1994b  
Leishmania amazonensis
(Pro) 
O1 P. oreades 
Brand et al., 2006b 
 H1 P. hypochondrialis Brand et al., 2006b 
Leishmania amazonensis
(Epi) 
H5 P. hypochondrialis
Brand et al., 2006b 
Leishmania chagasi (Pro) H5 P. hypochondrialis Zampa et al., 2009 
Plasmodium falciparum
(Trf) 
S3, S4 P. sauvagii Ghosh et al., 1997; Krugliak et al., 
2000 
Trypanosoma cruzi (Try) O1 P. oreades Brand et al., 2002 
 D1, D2 P. distincta Brand et al., 2002 
Virus    
HSV-1 S4 P. sauvagii Belaid et al., 2002 
HIV-1 S4 P. sauvagii Lorin et al., 2005; Zairi et al., 2009 
Table 1. Microorganisms susceptible to dermaseptins from anuran species belonging the 
genus Phyllomedusa. 
promising and attractive proposition as new antimicrobial therapeutics (Calderon et al., 
2009, 2010, 2011). Interestingly, the mechanism of interaction between AMP and microbial 
membrane inhibits a fast adaptation of parasites to the peptide action, as it requires a wide 
change in its membrane structure or composition, demanding a significant great metabolic 
change in a short period of time, in contrast to drugs of intracellular action (Phillips, 2001).  
The emergence, increased prevalence and rapid spread of extremely multidrug resistant 
pathogenic microorganisms together with the increased use of immunosuppressive 
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therapies, and the association with HIV co-infection present a serious challenge to public 
health systems around the world. The lack of therapeutic options against these pathogens 
has stimulated research into new bioactive molecules from the biodiversity as a source of 
more efficient (low toxicity and major potency) mechanisms for infection control (Calderon 
et al., 2009; Vaara, 2009). 
The interest in the development of new forms of anti-infective agents such as those based on 
AMPs from anuran skin as therapeutic agents has been increased (Rinaldi, 2002; Xiao et al., 
2011). Thus, they are likely to be active against pathogens and even those that are resistant 
to conventional drugs. Many peptides have been isolated and shown to be effective against 
multi-drug resistant pathogens. According to Xiao and co-workers (2011), more than 500 
AMPs have been identified from amphibians. This number of peptides described 
is insignificant when compared to all the potential represented by the amphibian global 
fauna, that are composed of much more than 6,000 species, with increases new species every 
year. According to Jared & Antoniazzi (2009), from the toxinology viewpoint, is possible 
imagine that with more than 6,000 species, should be at least 6,000 kinds of poison and 
hundreds of thousands of new bioactive molecules to be discovered.  
Of a total of 49 anuran families (Frost, 2011) only 10 have had part of their peptides 
identified, as can be observed in Table 2. Only members of the Ascaphidae, Bombinatoridae, 
Hylidae, Hyperoliidae, Leiuperidae, Leptodactylidae, Myobatrachidae, Pipidade, Ranidae 
families have been examined in order to discover new bioactive peptides. Members of the 
families Hylidae and Ranidae have received more attention, with a high number of peptide 
families characterized. The abundance of AMPs in frog skin is remarkable and constitutes a 
rich source for the design of new pharmaceutical molecules. Unfortunately, several anuran 
species have become extinct due to the events related to the amphibian decline before their 
bioactive molecules have had a chance to be discovered, such as the golden toad Bufo 
periglenes (Bufonidae) (Figure 4). 
 
Suborder Family (conservation 
status) 
Peptide identified 
Archaeobatrac
hia 
Ascaphidae Ascaphin, Bradykinin, Skin secreted peptide, Tryptophyllin 
 Bombinatoridae Bombesin, Bombinin, Bradykinin, Maximin, Tryptophyllin, 
Thyroliberin 
 Discoglossidae (EX) Alytesin 
 Leiopelmatidae (CR) none 
Mesobatrachia Megophryidae (CR) none 
 Pelobatidae none 
 Pelodytidae none 
 Pipidae (CR) Antimicrobial peptide, Caerulein, Dorphin, Leap2 protein, 
Levitide, Magainin, Midkine, Midkine, Peptide pGQ, 
Peptide PYLa/PGLa, Pleiotrophin, Xenopsin, Xenoxin 
 Rhinophrynidae none 
 Scaphiopodidae none 
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Suborder Family (conservation 
status) 
Peptide identified 
Neobatrachia Allophrynidae none
 Aromobatidae (CR) none
 Arthroleptidae (CR) none
 Brachycephalidae none
 Brevicipitidae none
 Bufonidae (EX, EW, CR) Neurotensin, Seritocin
 Calyptocephalellidae 
(CR)
none
 Centrolenidae (CR) none
 Ceratobatrachidae (CR) none
 Ceratophryidae (CR) none
 Ceuthomantidae none
 Craugastoridae (EX, CR) none
 Cycloramphidae (CR) none
 Dendrobatidae (CR) none
 Dicroglossidae (EX, CR) none
 Eleutherodactylidae 
(CR) 
none
 Heleophrynidae (CR) Bradykinin
 Hemiphractidae (CR) none
 Hemisotidae none
 Hylidae (EX, CR) Antimicrobial peptide, Aurein, Bioactive peptide, 
Bradykinin-potentiating peptide, Bradykinin, Caeridin, 
Caerin, Caerulein, Citropin, Dahlein, Deltorphin, 
Dermadistinctin, Dermaseptin, Dermatoxin, Dermorphin, 
Electrin, Fallaxidin, Frenatin, Hylaseptin, Hylin, Hyposin, 
Litorin, Maculatin, Novel peptide, Peptide TRP, Peroniin, 
Phyllocaerulein, Phyllokinin, Phyllomedusin, Phylloseptin, 
Pseudin, Rothein, Rubellidin, Skin secreted peptide, 
Splendipherin, Tryptophyllin, Uperin
 Hylodidae (CR) none
 Hyperoliidae (CR) Caerulein-like, FMRFamide-related, Galensin, Hylambatin, 
Kasseptin, Kassinakinin, Kassinatuerin, Kassinin, Kassinin, 
Kassorin, Tachykinin
 Leiuperidae (CR) Bradykinin, Phyllokinin, Physalaemin
 Leptodactylidae (CR) Aggression-stimulating peptide, Leptoglycin, Ocellatin, 
Ranaspumin
 Limnodynastidae (CR) none 
 Mantellidae (CR) none 
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Suborder Family (conservation 
status) 
Peptide identified 
Neobatrachia Micrixalidae (CR) none
 Microhylidae (CR) none
 Myobatrachidae (EX, 
CR) 
Bombesin, Crinia-angiotensin, Deserticolin, Dynastin, 
Fletcherin, Kassinin, Riparin, Rugosauperolein, Signiferin, 
Substance P-like, Uperin, Uperolein
 Nasikabatrachidae none
 Nyctibatrachidae none
 Petropedetidae (CR) none
 Phrynobatrachidae none
 Ptychadenidae none
 Pyxicephalidae (CR) none
 Ranidae (EX, CR) Atrial natriuretic factor, Bombesin, Bradykinin, Brevinin, 
Calcitonin, Chensinin, Gaegurin, Galanin, Granuliberin, 
Guentherin, Hydrin, Japonicin, Lectin-like, Melittin-like, 
Neurokinin, Neuromedin, Neurotensin, Nigrocin, 
Odorranain, Orexigenic neuropeptide, Palustrin, Peptide 
tyrosine arginine, Ranacyclin, Ranakinin, Ranalexin, 
Ranamargarin, Ranatachykinin, Ranatensin, Ranatuerin, 
Rugosin, Temporin, Tigerinin, Vasoactive intestinal peptide 
 Ranixalidae (CR) none
 Rhacophoridae (EX, CR) none
 Sooglossidae none
 Strabomantidae (CR) none
*According to the IUCN (2011), of the 6,260 amphibian species assessed, nearly one-third of species 
(32.4 %) are globally threatened or extinct, representing 2,030 species. Thirty-eight of the 2,030 species 
are considered to be Extinct (EX), and one Extinct in the Wild (EW). Another 2,697 species are not 
considered to be threatened at present, being classified in the IUCN Categories of Near Threatened or 
Least Concern, while sufficient information was not available to assess the status of an additional 1,533 
species. It is predicted that a significant proportion of these Data Deficient species are likely to be 
globally threatened (IUCN, 2011; Frost et al., 2008). 
Table 2. Anuran families ordered by suborder according to Frost (2011) with current status 
informed by IUCN* and peptide family described for each one deposited in the 
UniProtKB/Swiss-Prot. Current status are designated by the presence of extinct species 
(EX), extinct species in the wild (EW), and/or critically endangered species (CR) according 
to Frost and co-workers (2008). 
Since the first peptide was isolated from the Phyllomedusa skin, the Phyllokinin, a 
bradykinyl-isoleucyl-tyrosine O-sulfate from P. rohdei in 1966 by Erspamer’s research group 
(Anastasi et al., 1966), the number of anuran peptides discovered has increased 
exponentially (Calderon et al., 2011), but is still far from its real potential, which is 
evidenced by the observation that for every new anuran species studied new peptides are 
found, with homologies to hormones, neurotransmitters, antimicrobials, and several other 
peptides with unknown biological activity. 
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Fig. 4. Golden toad Bufo periglenes (Bufonidae) (EX) from Costa Rica (male), also called 
the Monteverde golden toad, or the Monte Verde toad. First described in 1966 (Savage, 
2002), is considered extinct by the IUCN since 1989 (IUCN, 2011), before its content of 
bioactive molecules could be researched (Image from the U.S. Fish and Wildlife Service's 
online digital media library, public domain). 
Nowadays, it is possible to carry out transcriptome analysis in order to build a robust cDNA 
library only with the secretions from a single living specimen (Chen et al., 2003b). The 
emergence of modern high-throughput molecular technologies involving de novo peptide 
sequencing via tandem mass spectrometry, cDNA cloning, and pharmacological screening 
applied to peptide discovery allowed fast structural data analysis and the generation of 
peptide sequence libraries, which in turn increased the capacity of peptide characterization, 
thus reducing the amount of samples needed (Shaw, 2009), which reduces significantly the 
impact on the amphibian populations researched by the reduction of the number of 
individuals necessary to perform bio prospection research.  
6. The resistance crisis: Increasing need for new antimicrobials 
Recently, antibiotic-resistant infections have reached unprecedented levels, some public 
health specialists and scientists have been warning that the antibiotic-resistant 
microorganisms strains, or superbugs, outstrip our ability to fight them with existing drugs. 
It is estimated that in 2007 approximately 25,000 patients died in the European Union, 
Iceland and Norway from an infection due to antibiotic-resistant bacteria that is able to 
outsmart even the newest antibiotics, such as Staphylococcus aureus, methicillin resistance 
(MRSA); S. aureus, vancomycin intermediate resistance and vancomycin resistance 
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(VISA/VRSA); Enterococcus spp. (e.g. Enterococcus faecium), vancomycin resistance (VRE); 
Streptococcus pneumoniae, penicillin resistance (PRSP); Enterobacteriaceae (e.g. Escherichia coli, 
Klebsiella pneumoniae), third-generation cephalosporin resistance; Enterobacteriaceae (e.g. K. 
pneumoniae), carbapenem resistance; and Non-fermentative Gram-negative bacteria (e.g. 
Pseudomonas aeruginosa), carbapenem resistance. In addition, infections due to any of these 
antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days and 
extra in-hospital costs of more than EUR 900 million (European Centre for Disease 
Prevention and Control/European Medicines Agency [ECDC/EMEA] Joint Working 
Group, 2009). The situation has reached to a critical point.  
One example of this situation is the emergence and rapid spread of extremely multiresistant 
pathogenic microorganisms endowed with new antibiotic resistance mechanisms such as 
New Delhi metallo-beta-lactamase-1 (NDM-1), an enzyme that makes bacteria resistant to a 
broad range of beta-lactam antibiotics, including the carbapenem family of antibiotics 
(except aztreonam), one of last resort for many bacterial infections, such as Escherichia coli (E. 
coli) and Klebsiella pneumoniae (Kumarasamy et al., 2010; Nordmann et al., 2011; Richter et al., 
2011). This gene has been identified in strains that possess other resistance mechanisms 
contributing to their multidrug resistance patterns, because these bacteria have often been 
referred to in the news media as “superbugs” because infections caused by them are 
difficult to treat successfully (Raghvendra et al., 2011). Most isolates with NDM-1 enzyme 
are resistant to all standard intravenous antibiotics for treatment of severe infections (Health 
Protection Agency [HPA], 2009a,b). It has been recently extensively reported from the 
United Kingdom, India and Pakistan and, albeit to a lesser extent, from a number of other 
countries worldwide (Nordmann et al., 2011). 
The emergence of multiresistant pathogenic microorganisms, increased use of 
immunosuppressive therapies, and the association with HIV co-infection, represent a serious 
public health problem with high mortality and morbidity rates, such as Cryptococcus, 
Cryptosporidium and Leishmania (Abu-Raddad et al., 2006; Pukkila-Worley & Mylonakis, 2008; 
Rivas et al., 2009; Vaara, 2009). The critical problem represented by the limited therapeutic 
options for increasing multidrug resistance in Gram-negative bacteria, in particular 
Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, have forced 
infectious disease clinicians and microbiologists to reappraise the clinical application of 
polymyxin antibiotic, a cyclic peptide with a long hydrophobic tail, discovered more than 50 
years ago (Li et al., 2006). Polymyxin is usually active in vitro (though not vs. Morganella 
morganii, an intrinsically resistant species) but of uncertain clinical efficacy, especially in 
pneumonia, owing to poor lung penetration. The Antibiotic Resistance Monitoring & 
Reference Laboratory (ARMRL) from the HPA Centre for Infections with the pharmaceutical 
industry is urgently reviewing the activity of both experimental and outdated antibiotics in 
order to develop alternative chemotherapies for NDM-1 (HPA, 2009a,b). 
One of the greatest accomplishments of modern medicine has been the development of 
antibiotic therapies for potentially fatal infections by multidrug-resistant pathogenic 
microorganisms. Unfortunately, over the past two decades, the discovery and development 
of novel antibiotics has decreased while pathogen resistance to those currently available has 
increased (Li et al., 2006). 
According to the European Centre for Disease Prevention and Control (ECDC) and the 
European Medicines Agency (EMEA) with contributions from the international network 
Action on Antibiotic Resistance (ReAct), there is a need for more development of antibiotics 
that are effective against multidrug-resistant bacteria. The ECDC/EMEA Joint Working 
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Group, using data from the European Antimicrobial Resistance Surveillance System 
(EARSS) and two commercial databases of antibacterial agents in clinical development 
worldwide (Adis Insight R&D and Pharmaprojects) concluded that there is a gap between 
the burden of infections due to multidrug-resistant bacteria and the development of new 
antibiotics to tackle the problem; and that a European and global strategy to address this 
gap is urgently needed (ECDC/EMEA Joint Working Group, 2009). 
Limited therapeutic options against these pathogens demand urgent prospection of new 
bioactive molecules from the biodiversity as a source for more efficient (low toxicity and 
major potency) mechanisms of microorganism killing (Calderon et al., 2009; Vaara, 2009). 
The discovery of new lead compounds is important to subsidize the development of new 
chemicals with structural characteristics for large-scale production by the pharmaceutical 
industry at a feasible cost. The sources from the biodiversity, such as the skin of several 
amphibian and other vertebrate and invertebrate animals, plants, and microorganisms, have 
proved to be an inexorable source of antimicrobial molecules, with a broad spectra of 
activity (Calderon et al., 2009), specially against the drug-resistant pathogens described 
before, in which the AMPs have highlights in their potential therapeutical application as 
exposed in Table 1 (Gomes et al., 2007; Hancock, 1997; Hancock & Lehrer 1998; Koczulla & 
Bals, 2003).  
One interesting example is the cationic alpha-helical peptide Ascaphin-8 
(GFKDLLKGAAKALVKTVLF-NH2), from the skin secretion of the primitive anuran 
Ascaphus truei (Archaeobatrachia: Ascaphidae) (Conlon et al., 2004). This AMP shows broad-
spectrum antibacterial activity against clinical isolates of beta-lactamase producing bacteria 
such as Escherichia coli (MIC=1.5-6 microM) and Klebsiella pneumoniae (MIC=12.5-25 microM), 
as well as a group of miscellaneous beta-lactamase producing strains of Citrobacter, 
Salmonella, Serratia, and Shigella spp (Eley et al., 2007). According to Eley and co-workers 
(2007), Ascaphin-8 is also toxic to human erythrocytes (LC(50)= 55 microM), however, the L-
lysine-substituted analogs Lys10, Lys14, and Lys18 also displayed potent antibacterial 
activity while showing very low hemolytic activity (LC(50)> 500 microM). This result shows 
that peptide engineering could reduce toxicity of haemolytic AMPs, which makes possible 
the development of a drug delivery system association to improve the efficiency of 
Ascaphin-8 analogs to be used as a therapeutic peptide antibiotic against multidrug-
resistant pathogenic microorganisms.  
7. Peptide antibiotics: Nanotechnological approaches against superbugs 
According to Marr and co-workers (2006), therapeutic peptide antibiotics will have advantages 
over conventional antibiotics due to their diverse potential applications, such as single 
antimicrobials, in combination with other antibiotics for a synergistic effect, or as 
immunomodulatory and/or endotoxin-neutralizing compounds (Zasloff, 2002). In particular, 
the most potent agents have an unusually broad spectrum of activity against most Gram-
negative and Gram-positive bacteria, and also to fungi and even a variety of viruses, such as 
dermaseptins (Table 1). One of their advantages is their ability to kill multidrug-resistant 
bacteria (Marr et al., 2006). Compared with conventional antibiotics, these bacteria-killing 
peptides are extremely rapid and attack multiple bacterial cellular targets (Brogden, 2005). 
Despite their obligatory interaction with the plasmatic membrane, some peptides are able to 
perforate plasmatic membrane at their minimal inhibition concentration (MIC), a number of 
AMPs translocate across the membrane and affect cytoplasmic processes, including 
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inhibition of macromolecular synthesis, particular enzymes or cell division, or the 
stimulation of autolysis (Marr et al., 2006). Minimal inhibitory concentrations and minimal 
bactericidal concentrations often coincide (less than a two-fold difference), indicating that 
killing is generally bactericidal, a highly desirable mode of action (Marr et al., 2006). 
Furthermore, AMPs are not hindered by the resistance mechanisms that occur with 
currently used antibiotics (Zhang et al., 2005). Indeed, killing can occur synergistically with 
other AMPs and conventional antibiotics, helping overcome some barriers that resistant 
bacteria have against currently used antibiotics (Marr et al., 2006). 
Until then, many efforts have been carried out in order to use the AMPs in the development 
of new infection-fighting drugs applicable to new treatments of nosocomial infections and 
multidrug-resistant infections (Amiche et al., 2000), due to the skill of the AMPs to kill 
multidrug resistant strains of microorganism by a mechanism unlikely to induce antibiotic-
resistance. The development of new antimicrobials based on AMPs hold promises to 
medicine at the end of the classical antibiotic age by the emergence of the multidrug-
resistant microorganisms (Alanis, 2005; Arias & Murray, 2009; Nordmann et al., 2011). 
Even with the expected advantages in the use of AMPs as new antimicrobials for the post-
antibiotic age, several impediments to therapeutic peptides arise. According to Marr and co-
workers (2006), the main problem at the present moment is the cost of manufacturing 
peptides, which is economically unfeasible for the amounts of AMPs needed compared to 
other antibiotics, preventing the widespread clinical use of AMPs as a common antibiotic, 
and the shortage of studies thoroughly examining systemic peptide pharmacodynamic and 
pharmacokinetic issues, including peptide aggregation problems, the in vivo half-life of 
peptides (and particularly their susceptibility to mammalian proteases), and the required 
dosing frequency (Marr et al., 2006). Due to the specific characteristics of the AMPs, that 
differentiate them from other antibiotics, the development of new strategies for the 
therapeutic use of AMPs in medicine are necessary in order to reduce the amount of AMPs 
necessary to promote the therapeutic infection suppression effect, including the addition of 
striking affinity to specific targets, efficiency at very low concentrations and negligible 
toxicity (Marr et al., 2006).  
From this viewpoint, the nanotechnological approach has become an efficient and viable 
alternative to promote the therapeutic application of AMPs by the use of nanocarriers in 
order to: protect the AMP from degradation; enhance AMP absorption by facilitating 
diffusion through epithelium; modification of pharmacokinetic and tissue distribution 
profile; and/or improving intracellular penetration and distribution. 
According to Couvreur & Vauthier (2006), over the past 30 years, the explosive growth of 
nanotechnology has burst into challenging innovations in pharmacology, which is in the 
process of revolutionizing the delivery of biologically active compounds.  
The main application of nanotechnology in cancer and infectious diseases pharmacology 
collaborate with the development of several approved forms of drug-targeting systems for 
the treatment of certain cancer and serious infectious diseases (Couvreur & Vauthier, 2006). 
One of the main examples is the Ambisome, a formulation of amphotericin B in liposome, 
which was marketed in 1996 (NeXstar now Gilead, Foster City, CA, USA). Before the 
nanostructured formulation, the toxicity of the leading compound against leishmaniasis and 
fungus, was 50- to 70-fold higher (Adler-Moore & Proffitt, 1993). This allowed the 
administration of more than 5-fold of the drug compared with conventional treatments. 
Thus, today it is considered the most efficient treatment for leishmaniasis and other fungal 
infections (Dupont, 2002; Ringden, 2002; Croft & Coombs, 2003). 
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Nanotechnology also seems to be a promising alternative to overcome the problems of the 
administration of peptides and of the new drug molecules coming out of the discovery 
pipeline. Nanotechnological based drug-targeting system carrying AMPs can be targeted to 
a precise location which would make the AMP much more effective, reducing the amount 
necessary to promote the antimicrobial action, as well as the chances of possible side-effects 
and production costs, making the therapeutic peptide antibiotics feasible economically 
compared to other antibiotics. 
In recent years, significant efforts have been devoted to the development of 
nanotechnological tools capable of enhancing the assembly and immobilization of AMPs in 
a synergistic way in biomedical devices (Huguenin et al., 2005; Siqueira et al., 2006; Zampa 
et al., 2007; Zucolotto et al., 2006, 2007).  
The structural and physico-chemical properties of the AMPs, such as the presence of a a-
helix fold and distribution of positive charges along the chain have allowed their use as 
active material in the development of bio-nanostructures with a potential application in 
therapeutics by the pharmaceutical industry and diagnosis (Zampa et al., 2009). These 
nanostructures include cationic nanoparticles, formed by the conjugation of cholesterol and 
AMPs, able to cross the blood–brain barrier for treatment of fatal Cryptococcal meningitis in 
patients with late-stage HIV infection (Wang et al., 2010); Polymyxin B conjugates with Au 
nanoparticles and CdTe quantum dots with improved antimicrobial activity and reduced 
toxicity to mammalian cells (Park et al., 2011); nanostructured thin films with immobilized 
AMPs as an agent intended to combat and prevent infection and formation of 
Staphylococcus biofilm (slimelike communities) related implant failure (Shukla et al., 2009); 
or as sensor elements for detection of Leishmania cells using cyclic voltammetry (Zampa et 
al., 2009). 
The use of the AMPs through nanotechnological innovation approach could provide an 
entirely novel way to treat and prevent infection and new systems for the detection and 
identification of infectious parasites. Nanotechnology could provide new ways to use lower 
amounts of AMPs with extreme efficiency in the infection suppression, by improving the 
cell, tissue, or organ’s specific biodistribution and increasing AMP potency by the 
association with nanotechnological structures. It is expected that in the forthcoming years 
nanotechnology will promote the emergence of new products for control and prevention of 
multidrug-resistance microbe infection arising from the identification and analysis of AMPs 
from anuran amphibian biodiversity. 
8. Final considerations 
Anuran amphibians are an enormous source of bioactive molecules with potential application 
for the development of new nanotechnological based therapies against multidrug-resistant 
microorganisms in the modern day public health system crisis. However, the emergence of 
chytridiomycosis, climate change, pollution, and destruction and/or alteration of natural 
habitats are producing a devastating effect on biodiversity causing the amphibian decline. 
One-third of the anuran species are extinct or threatened with extinction before its content of 
bioactive molecules, specially the antimicrobials, can be discovered. Without a concerted 
effort, biodiversity and humans could be dealing with the "nightmare scenario" of a 
worldwide spread of untreatable infections and disappearance of species with potential 
solutions to combat superbugs. A united push to inspect and preserve the biodiversity in order 
to produce subsides for the development of new drugs is urgently needed. 
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9. Abbreviations 
AMP   Antimicrobial peptide  
ARMRL  Antibiotic Resistance Monitoring & Reference Laboratory 
CR   Critically Endangered 
EARSS   European Antimicrobial Resistance Surveillance System  
ECDC   European Centre for Disease Prevention and Control 
EMEA   European Medicines Agency  
Epi   Epimastigote form 
EW  Extinct in the Wild  
EX   Extinct 
FSAP   Frog Skin Active Peptide 
HIV-1   Human Immunodeficiency Virus 1 
HPA   Health Protection Agency  
HSV-1   Herpes Simplex Virus 1 
IPCC   Intergovernmental Panel on Climate Change  
IUCN  International Union for Conservation of Nature and Natural Resources  
LC(50)  Lethal Dose, 50% 
Lys   Lysine 
MALDI-image Matrix Assisted Laser Desorption Ionization-Image 
MIC   Minimal Inhibition Concentration 
MRSA   Staphylococcus aureus, methicillin resistance 
NDM-1  New Delhi metallo-beta-lactamase-1  
Pro   Promastigote form 
PRSP   Streptococcus pneumoniae, penicillin resistance 
Trf   Trophozoite form 
Try   Trypomastigote form  
UniProt   The Universal Protein Resource 
VISA   Staphylococcus aureus, vancomycin intermediate resistance 
VRE   Enterococcus faecium, vancomycin resistance 
VRSA   Staphylococcus aureus, vancomycin resistance 
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